CapnoPharm is a global med-tech company advancing therapeutic aerosols for patients with peritoneal and pleural cancers. Their CapnoPen™ delivers Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in a controlled, intraoperative setting, enabling more precise drug delivery and opening avenues for research—from reformulating existing chemotherapy agents to next-generation therapies using siDNA, mRNA, nanomolecules, viruses, or immunotherapeutics. Through our partnership, Transmedic brings CapnoPen™ to leading cancer centres across Southeast Asia, providing surgeons with a predictable, distraction-free environment and supporting better patient care.